In The News

February 17th, 2026

Luminorix™ has been selected as the brand for our chemiluminescent diagnostic instrument, designed for high-sensitivity, laboratory-grade and confirmatory testing. The name reflects precision, sensitivity, and scientific rigor, while providing a scalable foundation for future instrument configurations.

AccuGlo™ has been selected as the brand for our digital intelligence platform and field-deployable assay family. The name conveys accuracy and clarity, reflecting AccuGlo’s role in delivering rapid screening in the field and transforming results—whether generated in the field or on Luminorix—into actionable insight through analytics, reporting, and surveillance. 

Together, Luminorix™ powered by the AccuGlo™ platform presents a unified diagnostics ecosystem—from field screening and confirmatory testing to insight and decision-making.

October 16th, 2025

NanoDetection Technology™ Named Top Biochip IP Technology.

We’re thrilled to be recognized by Semiconductor Review as the Top BioChip IP Technology of the Year, following industry nominations and a rigorous expert review. This achievement highlights our relentless drive to innovate and lead the next generation of biotechnology. We would also like to thank Lateral Dx and Richard Campbell for their continued support over the years.

August 8th, 2025

Welcome, Edward Smith

We’re proud to welcome Ed Smith, RPh, MBA, BCMAS, to the Board of Directors at NanoDetection Technology™!

Ed is a seasoned healthcare and life sciences executive with deep expertise across diagnostics, pharmaceuticals, and health systems. He brings a rare blend of clinical insight and strategic leadership—spanning commercialization, market development,​ interdisciplinary operations, and strategic alliances—that will be instrumental as we advance our proprietary chemiluminescence-based platform for infectious disease detection in human and veterinary health.

We’re thrilled to have Ed on board and look forward to the impact of his contributions.